HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2024, 26, 54

Remission Rates of Patients with Opioid Use Disorder Who Got Naltrexone Implantation: A Retrospective Study

Mustafa Danışman, Seyit Murat Aydın, Gamze Zengin İspir, Kübra Sezer Katar, and Mustafa Batuhan Kurtoğlu

Digital Object Identifier:
https://doi.org/10.62401/2531-4122-2024-54

Summary: Background: Opioid use disorder (OUD) is a public health issue worldwide with chronic and relapsing course. Antagonist pharmacotherapies such as naltrexone implantations seem to be promising. The current study aimed to investigate the remission rates of patients with OUD who got naltrexone implantation. Methods: This study was conducted by retrospectively scanning health records. Sociodemographic (e.g., age, gender, marital status, job status) and clinical data (e.g., age of first substance use, duration of opioid use disorder, treatment history, and retention duration after naltrexone implantation) were collected. Our hospital’s ethics committee ethically approved the study. Results: Patients (n=92) stayed in retention for 11.44 (±10.64) months. Based on multiple Poisson regression analyses, the duration of the “longest period of not using heroin” was the predictor of “post-implantation remission duration.” Continuation to substance use while implantation treatment and polydrug use were found to decrease the retention duration. Conclusion: Extended-release naltrexone is effective in managing opioid use disorder.

Keywords: drug implant; naltrexone; opioid use disorder; retention

 

EUROPAD - European Opiate Addiction Treatment Association
Brussels, Belgium, EU
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page